Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

This patient perspectives interview features Stacy Courtnay, who shared her experience managing rheumatoid arthritis during pregnancy.

The role of IL-6 is supported by preliminary data from a single-arm study in China using Actemra (tocilizumab). Sanofi is leading trials outside of the US, while its development partner ...

INCHEON, Korea & JERSEY CITY, N.J., May 27, 2025--Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations ...

Visit a quote page and your recently viewed tickers will be displayed here.

Generally, oral corticosteroids such as prednisone are prescribed first, with another drug, Actemra (tocilizumab), added on. Actemra is an interleukin-6 (IL-6) receptor blocker that blocks an ...